Luis Manso Sanchez

21PUBLICATIONS
208CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Health and ecological risk assessmentCauses and prevention of crime
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (21)

|Jun 26, 2026
Implementation of HER2DX Scores into Treatment Decisions in Early-Stage HER2-Positive Breast Cancer.

|May 15, 2026
Trastuzumab deruxtecan in HER2-expressing gynecologic cancers from DESTINY-PanTumor02: antitumor activity, safety, and exploratory biomarker analyses.

|Sep 10, 2025
A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer.

Luis Manso, Rodrigo Sánchez-Bayona, Juan Antonio Guerra

|Jul 01, 2025
Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma: the Asian cohort of the AtTEnd/ENGOT-EN7 trial.

Kenichi Harano, Roldano Fossati, Beatriz Pardo

|Apr 25, 2025
HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumab.

Rodrigo Sánchez-Bayona, Olga Martínez-Sáez, Denys Romero-Romero

|Mar 18, 2025
Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis.

Wolfgang Janni, Thomas W P Friedl, Tracy C Yab

Pageof 4

Frequent Collaborators

5 joint publications

José Ángel García-Saenz

4 joint publications

Antonio González-Martín

4 joint publications

Serafin Morales

3 joint publications

Rodrigo Sánchez-Bayona